Read More Pharma Industry News Can Sagimet turn denifanstat into a multi-indication platform and licensing engine beyond acne? Can Sagimet parlay its acne win into a licensing engine and platform biotech story? Explore how FASN inhibition is being redefined across diseases. byPallavi MadhirajuOctober 27, 2025